Clinical Trial: Efficacy and Safety of HRS-7535 in for Heart Failure With Preserved Ejection Fraction and Obesity

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820099) titled 'Efficacy and Safety of HRS-7535 in for Heart Failure With Preserved Ejection Fraction and Obesity' on Feb. 06.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 40-weeks' treatment period, and a 1-week safety follow-up visit period.

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Adults' Obesity With Heart Failure With Preserved Ejection Fraction

Intervention: DRUG: HRS-7535 tablet

HRS-7535 tablet.

DRUG: HRS-7535 tablet placebo

HRS-7535 tablet placebo.

Recruitment Status: NOT_YET_RE...